Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$56.28 USD

56.28
103,166

-0.04 (-0.07%)

Updated Aug 28, 2024 11:06 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma

by Zacks Equity Research

REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).

Regeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug

by Zacks Equity Research

Regeneron (REGN) suffers a delay in obtaining FDA approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma.

Kymera (KYMR) to Raise $225 Million Through Offering of Shares

by Zacks Equity Research

Kymera (KYMR) is in the process of selling approximately 2 million shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares in the offering.

Kinjel Shah headshot

How Should You Play AstraZeneca (AZN) After Q2 Beat, View Raise?

by Kinjel Shah

AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.

The Zacks Analyst Blog Highlights Meta Platforms, Sanofi, CME and The Cato

by Zacks Equity Research

Meta Platforms, Sanofi, CME and The Cato are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Meta, Sanofi & CME

by Sheraz Mian

Today's Research Daily features new research reports on 12 major stocks, including Meta Platforms, Inc. (META), Sanofi (SNY) and CME Group Inc. (CME), as well a micro-cap stock The Cato Corporation (CATO).

Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook

by Zacks Equity Research

Novavax (NVAX) posts dismal second-quarter results. It also slashes its total revenue guidance, citing lower COVID-19 vaccine uptake.

Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

Kymera (KYMR) reports a narrower-than-expected loss in the second quarter. The company expects the current cash balance to provide a runway into the first half of 2027.

The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi

by Zacks Equity Research

AstraZeneca, Ionis and Sanofi are included in this Analyst Blog.

Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent

by Zacks Equity Research

Regeneron's (REGN) decent second-quarter results can be attributed to strong uptake of Eylea HD sales and high Dupixent profits, even though lead drug Eylea is under pressure.

Sundeep Ganoria headshot

Novavax (NVAX) Stock Before Q2 Earnings: To Buy or Not to Buy?

by Sundeep Ganoria

On Novavax's (NVAX) second-quarter earnings call, investors will likely focus on the company's pipeline updates and collaboration revenue numbers from its recently entered deal with Sanofi.

Regeneron (REGN) Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales

by Zacks Equity Research

Regeneron (REGN) reports strong Q2 results, wherein both the top and bottom lines beat estimates due to higher Eylea HD and Libtayo sales and profits from Dupixent sales.

GSK Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance

by Zacks Equity Research

GSK's revenues benefit from strong growth across the Specialty Medicines and General Medicines segments. It raises guidance for earnings and sales for the full year.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News

by Kinjel Shah

AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary goals.

Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised

by Zacks Equity Research

Sanofi (SNY) posts mixed quarterly results, beating estimates for earnings while missing the same for sales. It raises its 2024 earnings growth expectations at CER.

AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View

by Zacks Equity Research

AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.

The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences

by Zacks Equity Research

Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.

Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports second-quarter 2024 results.

Ahan Chakraborty headshot

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

by Ahan Chakraborty

Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.

Sundeep Ganoria headshot

Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?

by Sundeep Ganoria

Novavax's (NVAX) shares continue to soar thanks to the recently signed partnership with Sanofi (SNY) to market its COVID-19 vaccine and develop novel COVID-19-influenza combination vaccines.

Kinjel Shah headshot

Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings?

by Kinjel Shah

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

Kinjel Shah headshot

AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy?

by Kinjel Shah

AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge with several candidates having blockbuster potential.

Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why

by Zacks Equity Research

Verona Pharma (VRNA) surges on the recent FDA approval for its lead drug, which is the first inhaled COPD product with a novel mechanism of action in more than 20 years.

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

by Zacks Equity Research

IDEAYA Biosciences (IDYA) and uniQure N.V. (QURE) are in the spotlight following positive pipeline updates.

Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies

by Zacks Equity Research

Kymera (KYMR) announces expansion plans of ongoing mid-stage studies on KT-474 (SAR444656) by partner Sanofi.